These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens. Repas TB J Am Osteopath Assoc; 2014 May; 114(5 Suppl 2):S14-21. PubMed ID: 24769504 [TBL] [Abstract][Full Text] [Related]
10. Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination. Moghissi ES J Am Osteopath Assoc; 2014 May; 114(5 Suppl 2):S22-9. PubMed ID: 24769505 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option. Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229 [TBL] [Abstract][Full Text] [Related]
12. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
13. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Bolli GB; Owens DR Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. Wang Y; Li L; Yang M; Liu H; Boden G; Yang G Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690 [TBL] [Abstract][Full Text] [Related]
15. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Lindamood CA; Taylor JR Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912 [TBL] [Abstract][Full Text] [Related]
16. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?]. Lüdemann J MMW Fortschr Med; 2011 Jul; 153 Suppl 2():56-63. PubMed ID: 23964469 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Mundil D; Cameron-Vendrig A; Husain M Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442 [TBL] [Abstract][Full Text] [Related]
20. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Carris NW; Taylor JR; Gums JG Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]